Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation.

Mol Cancer · 2025 · PMC12020020 · PMID 40275270

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp = 2e -45actually significant

Analysis using the GEPIA database revealed a highly significant correlation ( p = 2e -45 , R = 0.82) between these markers, providing new insights into the molecular mechanisms underlying PAAD progression and identifying new targets for diagnostic and therapeutic strategies.

also in 33,666 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.